Skip to main content

POTENCIAL TERAPEUTICO DE LA SUPLEMENTACION CON NICOTINAMIDA SOBRE LA ADIPOSIDAD, SEÑALIZACION DE LA INSULINA Y DE LA ENFERMEDAD HIGADO GRASO NO ALCOHÓLICO

PI21/00770

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

NAD+ Precursors and Intestinal Inflammation, Therapeutic Insights Involving Gut Microbiota

  • Niño-Narvión, Julia|||0000-0001-6514-0731
  • Rojo López, Marina Idalia|||0000-0001-6748-3156
  • Martinez-Santos, Patricia
  • Rossell, Joana|||0000-0003-1500-6379
  • Ruiz-Alcaraz, Antonio J.|||0000-0001-6913-0610
  • Alonso Pedrol, Núria|||0000-0001-9687-8050
  • Ramos-Molina, Bruno|||0000-0001-6804-5449
  • Mauricio, Didac|||0000-0002-2868-0250
  • Julve i Gil, Josep|||0000-0002-6531-2246
The oxidized form of nicotinamide adenine dinucleotide (NAD+) is a critical metabolite for living cells. NAD+ may act either as a cofactor for many cellular reactions as well as a coenzyme for different NAD+-consuming enzymes involved in the physiological homeostasis of different organs and systems. In mammals, NAD+ is synthesized from either tryptophan or other vitamin B3 intermediates that act as NAD+ precursors. Recent research suggests that NAD+ precursors play a crucial role in maintaining the integrity of the gut barrier. Indeed, its deficiency has been associated with enhanced gut inflammation and leakage, and dysbiosis. Conversely, NAD+-increasing therapies may confer protection against intestinal inflammation in experimental conditions and human patients, with accumulating evidence indicating that such favorable effects could be, at least in part, mediated by concomitant changes in the composition of intestinal microbiota. However, the mechanisms by which NAD+-based treatments affect the microbiota are still poorly understood. In this context, we have focused specifically on the impact of NAD+ deficiency on intestinal inflammation and dysbiosis in animal and human models. We have further explored the relationship between NAD+ and improved host intestinal metabolism and immunity and the composition of microbiota in vivo. Overall, this comprehensive review aims to provide a new perspective on the effect of NAD+-increasing strategies on host intestinal physiology.